NCT07240246Completed
Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults
Effect of a Dietary Supplement (FitLine TopShape) on the Incretin Response
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are not suitable for all patients, and adherence can be limited. Dietary supplements that influence appetite and satiety may represent an alternative or complementary approach. This study will evaluate whether a dietary supplement containing plant extracts stimulates the intestinal incretin response. The primary focus is the effect on glucagon-like peptide-1 (GLP-1) secretion. Secondary outcomes include dipeptidyl peptidase-4 (DPP-4), gastric inhibitory peptide (GIP), and insulin, as well as measures of appetite, satiety, food intake, and anthropometrics. The trial is designed as a 12-week, double-blind, randomized, placebo-controlled parallel-group study in adults with overweight or obesity (BMI 25-40, age 18-50). Participants will receive either the dietary supplement or placebo. Blood samples will be collected at baseline and after 12 weeks, both fasting and following capsule intake and a standardized liquid meal. Anthropometric measurements and visual analog scales (VAS) for hunger and satiety will also be assessed.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 24 Sept 2025
- Start date
- 24 Oct 2025
- Primary completion date
- 11 Mar 2026
- Lead sponsor
- FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation
- Diseases
- Obesity
- NCT number
- NCT07240246
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 24 Oct 2025 to the primary completion date, 11 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known allergy to ingredients in the administered substances
- Type 1 or 2 diabetes
- Acute infectious disease
- Renal insufficiency
Other
- Pregnancy
- Breastfeeding mothers
Who the study is looking for
- Signing the consent form
- BMI 25-40 kg/m²
- Age 18-50 years
Age in the registry: 18 years to 50 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Salzburger Universitatsklinikum Coordinator of this site? Confirm its status | Salzburg | Austria | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.